Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
75.56%
Operating Margin
63.84%
Net Margin
46.81%
Efficiency Metrics
Revenue per Expense Ratio
2.77
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
63.77%
Income Tax Rate
0.00%
EPS
1.8100000000
Balance Sheet Analysis
Current Ratio
1.65
Cash Ratio
1.64
Working Capital
$65.40M
Debt to Equity
0.26
Debt to Assets
19.76%
Equity Ratio
74.64%
Cash Flow Analysis
Operating Cash Flow Ratio
55.53%
Free Cash Flow Ratio
39.13%
CapEx to Revenue
16.40%
Dividends Paid
$135.85M
Stock Buybacks
$1.51M
Total Shareholder Returns
$137.37M
Cash Position Change
491.95%
Key Takeaways (2023 FY)
Increased dividend payments by 14.81%
Detailed Growth Metrics
Core Performance
Revenue
17.15%
Net Income
-23.51%
EPS
-30.65%
Operating Income
62.10%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
21.62%
Operating Cash Flow
25.46%
Free Cash Flow
65.31%
Balance Sheet Health
Assets
23.39%
Debt
0.10%
Book Value per Share
18.65%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
14.81%
Shares Outstanding
10.16%
Long Term Trends
3Y Revenue/Share
41.08%
5Y Revenue/Share
47.48%
3Y Dividend/Share
48.02%
5Y Dividend/Share
82.53%